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Introduction: Fecal microbiota transplantation (FMT) is commonly used for treatment of C. difficile 
infections (CDI), although prospective safety data are limited and real-world FMT practice and outcomes 
are not well described.  The FMT National Registry was designed to assess FMT methods and both safety 
and effectiveness outcomes from North American FMT providers.  
Methods: Patients undergoing FMT in clinical practices across North America are eligible. Participating 
investigators enter de-identified data into an online platform including FMT protocol, baseline patient 
characteristics, CDI cure and recurrence, and short and long-term safety outcomes.  
Results: Of the first 259 participants enrolled at 20 sites, 222 have completed short-term follow-up at 1 
month, and 123 have follow-up to 6 months; 171 (66%) are female. All FMTs were done for CDI, and 249 
(96%) used an unknown donor (e.g., stool bank). One-month cure occurred in 200 (90%); of these, 197 
(98%) received only a single FMT. Among 112 with initial cure who were followed to 6 months, 4 (4%) 
had CDI recurrence.  Severe symptoms reported within 1-month of FMT included diarrhea (5 (2%)) and 
abdominal pain (4 (2%)); 3 (1%) had hospitalizations possibly related to FMT. At 6 months, new 
diagnoses of irritable bowel syndrome were made in 2 (1%) and inflammatory bowel disease in 2 (1%).  
Conclusions: This prospective real-world study demonstrated high effectiveness of FMT for CDI with a 
good safety profile. Assessment of new conditions at long-term follow-up is planned as this registry 
grows and will be important for determining the full safety profile of FMT.  







Recurrent Clostridioides difficile infection (CDI) is common and increasing within the United States
1
. It is 
associated with significant morbidity and mortality
2
 and frequent failure of standard medical 
treatments
3
.  Fecal microbiota transplantation (FMT) has proven to be a highly efficacious therapeutic 
modality to prevent recurrent CDI
4 
 and increasing data support its use in severe or refractory cases
5
. 
FMT is permissible for CDI not responsive to standard therapy under a policy of enforcement discretion 
of the United States Food and Drug Administration (FDA). This policy, the widespread availability of the 
therapeutic substrate, and the ease of administration have facilitated the use of FMT for treatment of 
CDI. However, early adoption and expansion of FMT in clinical practice has allowed FMT to bypass the 
standard investigatory pathway in which large randomized controlled trials (RCTs) contribute important 
short- and long-term safety data before a product comes to market.  
While the value of FMT in treating recurrent CDI is clear, the potential long-term consequences are not 
known.  The gut is estimated to contain 1000 bacterial species containing 100-fold more genes than the 
human genome.  Viruses, bacteriophages, archaea and fungi contribute to this microbial community
6
 
which functions as an ‘organ’ with an immense impact on human health and disease, including host 
metabolism, physiology, nutrition and immune function
7
.  Recent evidence demonstrates long-term 
engraftment of donor microbes into the recipients of FMT
8
. A priori knowledge is not available regarding 
the impact of transferring these complex communities from one individual to another, although animal 
models and human studies indicate that manipulation of gut microbiota can affect host susceptibility to 
diseases such as obesity
9
 and inflammatory bowel disease (IBD)
 10-12 10-12 10-12 10-12 10-12 10-12 10-12 10-12 10-12
. As 
the practice of FMT and related therapeutic methods rapidly expand, it is crucial to determine the 
effectiveness and best practices of FMT techniques, and to assess the short-term and long-term safety.  
Furthermore, understanding FMT effectiveness and safety in “real-world” clinical settings is important 
6 
 
because many recurrent CDI patients are not eligible for clinical trials due to common comorbidities 
such as IBD and immunocompromised status
13 
and because interest in FMT for other indications is 
increasing.  
To address these needs, the American Gastroenterological Association (AGA) Institute, in partnership 
with other professional organizations, has developed an FMT National Registry to collect clinical and 
patient-reported outcomes. This registry, funded by a grant from the National Institute of Allergy and 
Infectious Diseases (NIAID), primarily aims to assess the short-term and long-term safety of FMT and 
other gut-related microbiota products. Secondary objectives include characterizing the effectiveness of 
FMT and other gut-related microbiota products, gathering information on FMT practice in North 
America, and promoting scientific investigation in FMT and the gut microbiome.  Here we report on the 
first 259 participants enrolled in the FMT National Registry. 
METHODS 
Study Design 
The FMT National Registry is an ongoing, prospective, observational, multicenter registry of North 
American participants who receive FMT for any indication and began enrolling patients in December 
2017.   The registry is administered by the AGA with grant support by the NIAID (award number 
R24AI118629). Partner organizations include the North American Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition (NASPGHAN), the Infectious Diseases Society of America (IDSA), and the 
Crohn’s & Colitis Foundation.  
 
This observational registry has no study-mandated protocol for FMT or follow-up visits.  Rather, 
participants are treated at the discretion of their providers. Diagnosis of CDI and need for FMT or 
7 
 
subsequent anti-CDI therapies was determined by individual registry sites. The registry was approved by 
Western Institutional Review Board, Inc. and all subjects provide written informed consent. De-
identified data are entered by investigators at participating sites into electronic case report forms on a 
data capture system maintained by Viedoc
TM
 (ACI Clinical, Bala Cynwyd, PA).  Data collection is overseen 
remotely by AGA under the supervision of a steering committee comprising experts in FMT, gut 
microbiome, clinical research, epidemiology, and informatics. Participant safety is reviewed at least 
yearly by an Observational Study Monitoring Board.  
 
Participating sites were primarily self-identified through an online survey created by AGA to gauge 
interest in the registry. Other sites were referred by members of the steering committee.  
 
Subjects 
Inclusion criteria are the ability to provide informed consent, receipt of FMT or another gut microbial 
therapeutic product within 90 days after providing consent, and access to internet and/or telephone. 
The only exclusion criterion is incarceration.  
Data Collection 
Data are collected regarding FMT methods (e.g., screening of donor and recipient, stool preparation, 
FMT delivery method), baseline characteristics of donors and recipients of FMT (e.g., demographic 
information, details on indication for FMT, body mass index, medical history, medications) (Supplement 
1). Severity of CDI was classified per published guidelines
14
. Pre-defined safety (short-term symptoms, 
new medical conditions, other adverse events) and effectiveness (e.g., cure and recurrence for CDI, IBD 
status) outcomes are provided on the electronic case report form (Supplement 2), which also allows 
free-text entry of additional outcomes.   
8 
 
Data are collected by the participating sites at baseline and at the following timepoints after the 
participant’s FMT procedure: 1 month, 6 months, 1 year, and 2 years. The registry protocol allows for 
these follow up data to be collected either at clinic visits or by telephone interview, as per local 
preferences at each site. This publication reports data at baseline, 1 month and 6 months. The data for 
this publication were extracted from the database on September 2, 2019. 
Outcomes for Analysis 
The primary outcome of effectiveness was cure of CDI assessed at 1 month (window 20-60 days) after 
FMT.  Cure was defined as resolution of diarrhea without need for further anti-CDI therapy. We also 
assessed cure of CDI at 6-months (window 120-240 days) after FMT.   
Safety outcomes included patient symptoms, infections, hospitalizations, deaths, and changes in current 
medical conditions or development of new medical conditions. One-month adverse events included 
those reported up to 60 days after FMT, whereas 6-month adverse events included those reported 
between 61 to 240 days after FMT.  
Results are reported descriptively without hypothesis testing. For categorical variables, proportions are 




Between December 5, 2017 and September 2, 2019, 259 participants with post-FMT follow-up were 
enrolled at 20 sites (Figure 1).   
9 
 
Table 1 lists baseline characteristics of the 259 participants.  Treated participants ranged in age from 1-
98 years with a median age of 63 years. Twenty (8%) of the participants were <18 year of age. Recipients 
were more commonly female than male (171 (66%) vs. 88 (34%)) and 238 (92%) were white. Of note, 
baseline comorbidities included irritable bowel syndrome (IBS) in 30 (12%), ulcerative colitis (UC) in 24 
(9%), and Crohn’s disease in 19 (7%).  Regional distribution in the U.S. was primarily in the Northeast 
(45%) and Midwest (43%). 
Indications  
All participants were treated with FMT for a diagnosis of CDI. The majority were diagnosed with CDI 
based on symptoms and stool testing, including polymerase chain reaction (163 (63%)), enzyme 
immunoassay (54 (21%)), or both (20 (8%)) (Table 2).   
Of the 259 participants with reported baseline CDI severity, most were moderate (115 (44%)) or mild (92 
(36%)) (Table 2).  Duration of CDI diagnosis pre-FMT varied from less than one week to 9 years with a 
median duration of 20 weeks. The mean number of CDI episodes reported prior to FMT was 3.5 (range 1 
to 15). Among the 15 cases with 1 prior CDI episode, 4 were severe, 7 moderate and 4 were mild, all 
were presumed to have failed standard anti-CDI therapy.  Almost all participants (236 (91%)) had a prior 
course of vancomycin and 141 (55%) had also received a vancomycin taper or pulse regimen. The 
median duration of vancomycin treatment was 14 days (range 1-203 days) and 146 of these participants 
(62%) had 2 or more courses of treatment. Among other prior CDI treatments, 103 (40%) had received 
metronidazole and 73 (28%) had been treated with fidaxomicin.    
FMT Methodology 
Almost all participants (249 (96%)) received FMT using an unknown donor, primarily from stool banks 
(OpenBiome (167 (67%)), other stool banks (73 (24%)) (Table 3). Sites using an alternate source of stool 
described site specific donor identification and screening techniques.  The median volume administered 
10 
 
was 250 ml (range 21-400 ml). The primary method of FMT delivery was colonoscopy (221 (85%)) 
followed by upper endoscopy (15 (6%)) (Table 3).  In all cases the site investigators planned a single dose 
protocol of FMT for CDI therapy.  
Outcomes 
Effectiveness 
Of the 259 participants, 222 returned within the 1-month follow-up window.  Of these, 200 participants 
(90%, 95% CI 85-93%) had CDI cure, with 197 (98%) requiring only a single FMT to achieve cure (Figure 
2).  Participants not included in this effectiveness outcome calculation included those whose first visit 
occurred before day 20 (n=9), after day 60 (n=28), or who were missing first visit data (n=6). Of the 
participants whose first visit occurred before 20 days, all were reported as cure and 6 participants 
remained cured at subsequent follow-up points; 3 participants did not have further follow up beyond 
this first visit.  Post-hoc analysis of the 256 participants who had a follow-up visit recorded at least 20 
days after FMT (first day of the 1-month visit window) was performed, and 224 (88%, 95% CI 83-91%) 
were reported as cure. Analysis of an intent-to-treat population of all participants entered, including 
those lost to follow-up, still reveals a cure rate of 224/259 (86%, 95% CI 82-90%). 
 
Of the 259 participants, 123 had both 1-month and 6-month follow-up within the pre-specified 
windows. Of the 112 participants cured at 1-month and with follow up at the 6-month time point, 4 (4%) 
had developed recurrent CDI at a median of 8 weeks (range 8-14 weeks) post-FMT (Figure 2).  Of the 11 
participants failing initial FMT who were followed to 6 months, 7 (64%) were reported as cured at this 
later timepoint. Treatments administered to these 7 participants included metronidazole and/or 
vancomycin (6 (86%)) or repeat FMT (1 (14%)). Participants not included in the 6-month effectiveness 
outcome calculation included those who reported cure at the first visit but withdrew (n=4) or whose 
11 
 
visit occurred after the data pull cutoff (n=80).   Post-hoc analysis of 145 participants with data reported 
within the 6-month visit window, regardless of whether they had 1-month follow-up visit, was 
performed and 128 (88%, 95% CI 82-93%) were reported as cure.   
Short-term (one-month) adverse events 
Three procedure-related complications occurred: 1 colonoscopic perforation and 2 episodes of 
gastrointestinal bleeding. The perforation occurred at a biopsy site in an 82-year-old woman with a 
history of microscopic colitis; the participant underwent a colectomy with full recovery.  One episode of 
mild and self-limited rectal bleeding was reported at telephone follow-up after colonoscopic FMT.  One 
participant experienced post-polypectomy bleeding which required hospitalization.  
Post-FMT symptoms were common with 106 (45%) participants reporting at least one symptom. The 
most common symptoms were non-CDI diarrhea (n=69), abdominal pain (n=39), bloating (n=34) and 
constipation (n=24).  A total of 212 symptoms was reported, of which 13 (6%) were severe (Table 4).  
Infections were reported in 11 participants (5%), including 2 (1%) which were felt by the site investigator 
to be possibly related to the procedure:  Bacteroides fragilis bacteremia in one participant with severe 
diarrhea pre- and post-FMT, and enteropathogenic E. coli on a multiplex polymerase chain reaction stool 
panel in a participant who reported soft-stools following FMT. Other infections in 9 participants were 
felt to be unrelated and included urinary tract infection (UTI) (n=4), pneumonia (n=3), E. coli bacteremia 
(n=1) and tooth infection (n=1) (Table 4).  
Hospitalizations were reported in 27 (12%) participants within 1 month after FMT.  The most common 
reason for hospitalization was CDI recurrence (n=6). Three hospitalizations were reported as possibly 
related to the FMT procedure: continued diarrhea, abdominal pain, dehydration, and fever (n=1), UC 
flare (n=1), and perforation (n=1).  No participant deaths were reported at 1-month follow-up. 
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Participants who missed the visit (n=6) or whose visit fell after 61-days post FMT (n=22) were not 
included in the short-term safety analysis.  
Six-month adverse events 
Among the 156 participants with data collected at 6-month follow-up, 6 participants (4%) had one or 
more new infections diagnosed between 1 and 6 months including  pneumonia; Campylobacter 
infection; cellulitis and infected arteriovenous fistula with methicillin-resistant Staphylococcus aureus 
(MRSA) bacteremia; pneumonia with streptococcus pharyngitis; UTI; and pneumonia, UTI and acute 
kidney injury +/- aspiration pneumonia. (Table 5) All infections resolved.  
Hospitalizations were reported in 30 participants (19%) between 1 and 6 months after FMT (Table 5). 
The most common reason was an infection other than CDI: UTI (n=2); pneumonia (n=1); MRSA (n=1); 
septicemia (n=1); and 1 participant with cellulitis, infected arteriovenous fistula and MRSA bacteremia. 
Three participants were hospitalized for CDI recurrence. 
Two (1%) participants had a new diagnosis of IBS and 2 (1%) had a new diagnosis of IBD (both UC) within 
6 months after FMT (Table 5).  
Four participants died, but no deaths were attributed to FMT; the causes reported by the site 
investigators were chronic obstructive pulmonary disease, ovarian cancer, septicemia, and worsening 
dementia. 
Discussion  
This is the largest prospective study to date of effectiveness and safety outcomes after FMT.  CDI cure 
rates were excellent at approximately 90% and in line with those reported in RCTs of FMT
15-18
 and in a 
National Pediatric FMT Registry
19
.  Thus, patients can expect to achieve high rates of success with FMT 
for refractory CDI in standard clinical practice.  In addition, CDI cure could be achieved with only 1 FMT 
13 
 
in virtually all cases.  Finally, we found FMT response to be durable, with recurrence in the 6 months 
after successful FMT seen in only 4% of participants, occurring most often within 2 months.  For those 
with unsuccessful FMT at one month, most could still achieve cure by 6 months using either standard 
antibiotic therapy or following repeated FMT.   
Risk of infection transmission from FMT has been of great concern, highlighted by a recent FDA 
report of 2 cases of extended spectrum beta-lactamase producing  E. coli infections (one fatal) believed 
to have been transmitted by donor stool
20
.  Most donors in our cohort were from a stool bank that 
screens extensively for transmissible pathogens, including multi-drug resistant organisms. Short-term 
infections reported in registry participants, so far, have been few in number, occurring in 5% of those 
treated, with only 1% felt possibly related to the FMT.  Indeed, infectious complications after FMT 
appear remarkably rare, as was reported in a recent systematic review which showed infections 
occurred in only 2.5% of over 1,000 patients treated
21
. Even high-risk immunocompromised patients 
appear to have a low risk of contracting an infection related to FMT
22, 23
. However, infections after FMT 
may not be recognized or recorded in retrospective studies not designed specifically to assess safety 
outcomes, highlighting the importance of continued collection of data such as these in prospective 
studies with pre-defined safety and effectiveness outcomes.  
Other short-term adverse events after FMT can be the result of the procedure used to 
administer the treatment.  Fatal aspiration pneumonia was previously reported as a complication of 
FMT administered by nasoduodenal tube
24
.  Most sites in this registry administer FMT colonoscopically, 
and 3 colonoscopy-related complications were reported. They were considered related to the procedure 
itself rather than the FMT.  There may be advantages to administering FMT via lower endoscopy, 
including possibly increased efficacy
25, 26
 and the ability to examine the colon for other underlying 
pathology, such as IBD.  However, it is important to weigh the risk of procedural complications and 
associated sedation, as well as medical costs, against the benefits, especially in patients who are 
14 
 
financially vulnerable, frail, or have significant cardiopulmonary comorbidities. Indeed, the preferred 
method of administration may vary depending on the clinical situation and local expertise. The majority 
of FMTs in this country are being done by gastroenterologists using material from donor stool banks 
with the preferred method of administration being colonoscopic.  As the registry expands, we plan to 
target additional sites that use other methods of delivery, as we hope to be able to compare the 
effectiveness and safety of FMT administered by different routes, such as capsule, enema, or naso-
intestinal tubes.  
The risk of further CDI recurrences is known to increase with each subsequent CDI episode, with 
rates as high as 65% after a second recurrence
3, 27
. Though uncontrolled, our data are compelling in that 
the cycle of recurrent CDI was broken in a large number of participants who had failed 2 or more 
previous courses of conventional antibiotic therapy. RCTs have restrictive inclusion and exclusion criteria 
and thus are not fully representative of an unselected real-world population of patients with CDI. In fact, 
the majority of patients with recurrent CDI do not qualify for RCTs of microbiota-based therapeutics
13
 
because of co-comorbidities such as IBD or immunocompromised status, highlighting the value of 
registry studies such as this, which allow the collection of important effectiveness and safety data that 
are more reflective of the real-world population.   
Weaknesses of this study are inherent to the design and included missing or incomplete data, 
multiple follow-up visits falling outside of pre-specified windows, patients lost to follow-up, and 
potential for recall bias when patients were queried at follow-up.   Donor screening protocols also varied 
across the participating sites, leading to possible differences in the potential for transmission of 
infectious agents such as enteropathogenic E. coli. Additionally, because this was an observational study 
rather than a clinical trial, FMT and post-FMT practice was not mandated but rather at the discretion of 
FMT providers at each site. Indications for FMT, diagnoses of CDI, and determinations of cure were 
made based on clinical grounds by site investigators. Transient episodes of diarrhea which resolved 
15 
 
without further anti-CDI therapy were not considered failures of FMT and differing CDI testing methods 
(e.g., PCR, toxin enzyme immunoassay) were used by investigators.  In real-world settings, the diagnosis 
of recurrent CDI is commonly made based on compatible symptoms and anti-CDI therapy started 
without confirmatory testing.  Registry staff queried site investigators to obtain missing or incomplete 
data or for clarification or additional information around serious adverse events.  Although this report 
includes results from 20 different geographically diverse centers around the U.S., we cannot conclude 
that they are wholly representative of FMT practice and results nationally. The Registry sites tend to be 
larger volume centers with an interest in FMT 
We developed the FMT National Registry in order to provide a real-world view of clinical 
practice, patient outcomes, safety, and comparative effectiveness
28
.    Our registry is designed to provide 
long-term assessment for up to 10 years to answer the most pressing safety question regarding FMT:  
whether FMT increases the risk of developing other medical conditions in the years after it is performed.  
Indeed, this was a lesson the medical community learned from the inadvertent transmission of human 
immunodeficiency virus and hepatitis C virus by blood transfusion.  A variety of conditions postulated to 
potentially be influenced by the gut microbiota (e.g., diabetes, cancer, cardiovascular events, 
autoimmune disease) are pre-specified to be collected from physicians for up to 2 years and patients for 
up to 10 years in the Registry. To assess whether such conditions are increased in patients receiving 
FMT, we plan to use a retrospective control group from an insurance claims database of patients with 
recurrent CDI treated with at least 3 courses of antibiotics rather than FMT. 
We anticipate adding registry sites within the next 6 months, which will increase the number, as 
well as geographic and demographic diversity, of participants recruited.   Obtaining information on 
current FMT methods in North America is an important first step in characterizing FMT practice with the 
future goal of standardizing and optimizing FMT. In addition, several gut microbiota-derived products 
16 
 
are in late phases of clinical development and likely will be approved for use in the near future. These 
products are hoped to reduce concerns regarding donor screening and infection transmission, but their 
real-world safety and effectiveness will be important to determine. We also anticipate the Registry will 
evaluate patients treated with these new products once released.
29-31
  
Real-world evidence is becoming increasingly important in health care and is a recent interest of 
the FDA in monitoring for adverse events and regulatory decision making
32
.  FMT practitioners together 
with the research community have the responsibility to protect the safety of patients receiving FMT and 
the opportunity to gain tremendous new insights into the biology of the human gut microbiome. 
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Table 1. Subject demographics. 
 
Characteristic N (%) 
Age  
< 18 years 20 (8) 
18 – 55 years 77 (29) 
> 55 years 162 (63) 
Sex  
Female 171 (66) 
Male 88 (34) 
Race  
White 238 (92) 
Black/African American 5 (2) 
Asian 3 (1) 
Other 4 (2) 
Unknown 9 (3) 
Ethnicity  
Not Hispanic/Latino 246 (95) 
Hispanic/Latino 11 (4) 
Not reported 2 (1) 
Region  
U.S. Northeast 117 (45) 
U.S. Midwest 111 (43) 
U.S. South 18 (7) 
U.S. West 13 (5) 
Comorbidities at baseline (≥ 5% prevalence)
a
 
Hypertension 82 (32) 
Hyperlipidemia 70 (27) 
Anxiety 48 (19) 
IBD 45 (17) 
Ulcerative colitis 24 (9) 
Crohn’s disease 19 (7) 
Indeterminate colitis 2 (1) 
Depression 40 (15) 
Cancer 35 (14) 
Hypothyroidism 32 (12) 
Cardiovascular disease 31 (12) 
  
Irritable bowel syndrome 30 (12) 
Type 2 diabetes  28 (11) 
Asthma or allergic/atopic conditions 15 (6) 
a
 Note some participants had more than one comorbidity. 
  
Table 2. FMT indication and related characteristics. 
 
Characteristics N (%) 
FMT indication  
CDI 259 (100) 
Method of CDI diagnosis  




Symptoms, EIA and PCR
1 
20 (8) 







Not reported 1 (<1) 
CDI severity  
Mild 92 (36) 
Moderate 115 (44) 
Severe 48 (19) 
Severe-complicated 2 (1) 
Not reported 2 (1) 
CDI duration  
< 1 month 14 (5) 
1-6 months 149 (58) 
7-12 months 61 (24) 
13-24 months 17 (7) 
> 24 months 16 (6) 
Not reported 2 (1) 
Number of prior CDI episodes  
1 15 (6) 
2 34 (13) 
3 110 (42) 
4 56 (22) 
5 or more 42 (16) 
Not reported 2 (1) 
Prior treatments for CDI  
Vancomycin 236 (91) 
Vancomycin taper/pulse 141 (54) 
Metronidazole 104 (40) 
Fidaxomicin 73 (28) 
Probiotics 44 (17) 
Other treatments 14 (5) 
No prior treatments 5 (2) 
1
 EIA = enzyme immunoassay; PCR = polymerase chain reaction 
  
Table 3. Summary of FMT methodology. 
 
 N (%) 
Stool donor type  
Unknown donor 249 (96) 
OpenBiome 167 (67) 
Other stool bank 73 (29) 
Source not reported 9 (4) 
Known donor 8 (3) 
Not reported 2 (1) 
Primary method of FMT delivery  
Colonoscopy  221 (85) 
Upper endoscopy  15 (6) 
Oral capsule  8 (3) 
Sigmoidoscopy  2 (1) 
Naso-intestinal tube  2 (1) 
Colonoscopy and upper endoscopy (same procedure date) 2 (1) 
Other 3 (1) 






Figure 2. FMT effectiveness. 
  
Table 4. Adverse events reported up to 1 month after FMT. 
 N (%) 
Common symptoms of any severity 
with more than 2% prevalence 
 
Diarrhea 69 (30) 
Abdominal pain 39 (17) 
Bloating 34 (15) 
Constipation 24 (10) 
Nausea and/or vomiting 15 (6) 
Severe symptoms  
Diarrhea 5 (2) 
Abdominal pain 4 (2) 
Bloating 1 (<1) 
Constipation 1 (<1) 
Other 2 (1) 
New infections  
None 219 (95) 
Unrelated to FMT 9 (4) 
Possibly related to FMT 2 (1) 
Bacteroides fragilis 1 (<1) 
Enteropathogenic E. coli  1 (<1) 
Not reported 1 (<1) 
Hospitalizations  
None 204 (88) 
Unrelated to FMT 24 (10) 
Possibly related to FMT 3 (1) 
Perforation 1 (<1) 
Ulcerative colitis flare 1 (<1) 
Diarrhea, abdominal pain, fever 1 (<1) 
 
  
Table 5. Adverse events reported between 1-6 months after FMT. 
 N (%) 
New diagnoses  




Irritable bowel syndrome - diarrhea 2 (1) 
Ulcerative colitis 2 (1) 
Other
b
  22 (14) 
Not reported 10 (6) 
Serious infections  
No 140 (90) 
Yes
a
 6 (4) 
Pneumonia 1 (<1) 
Urinary tract infection 1 (<1) 
Campylobacter infection 1 (<1) 
Cellulitis 1 (<1) 
Infected AV fistula/MRSA bacteremia 1 (<1) 
Streptococcus pharyngitis 
Pneumonia/Acute kidney injury +/- aspiration 
pneumonia/Urinary tract infection 
1 (<1) 
1 (<1) 
Not reported 10 (6) 
Hospitalizations  




Infection other than CDI 8 (6) 
CDI recurrence 3 (2) 
Other
c
 30 (20) 
Deaths  
Unrelated to FMT 4 (3) 
Related to FMT 0 (0) 
a
 Note some participants had more than one diagnosis or reason for hospitalization. 
b 
All other conditions were N = 1: Abdominal aortic aneurysm, Barrett’s esophagus, belching, 
cardiovascular disease, COPD, colon cancer, dermatitis, fistula between Indiana pouch and bowel, GERD, 
hair loss, jaw cancer, left heart failure, left inguinal hernia, neurologic disorder, osteopenia, 
osteoporosis, overflow diarrhea, pelvis floor dysfunction, pregnancy, prostate cancer, snoring, urinary 
tract infection.  
c
 Other reasons for hospitalization included acute episode of croup, acute right anterior cerebral artery 
stroke, breast implant removal, breathing, cirrhosis, colitis, constipation, Crohn’s disease flare, 
dehydration (2 cases), diverticulitis, abnormal liver function tests, fainting, hysterectomy, intestinal 
obstruction, lung transplant symptoms, overflow diarrhea, peritoneal dialysis catheter placement, 
potential ulcerative colitis flare, primary sclerosing cholangitis flare (worsening of left hepatic biliary 
duct inflammation), robotic prostatectomy, seizure, severe sepsis/septic shock, surgery for recurrent 
colon cancer, ulcerative colitis flare, ulcerative colitis laparoscopic ileal pouch anal anastomosis with 




What You Need to Know 
Background and context: Fecal microbiota transplantation (FMT) is widely used for treatment of  C. 
difficile infection unresponsive to standard therapy, although a paucity of prospective and real-world 
data exists.  
New Findings: FMT led to a cure of C. difficile infection in 90% of patients in a registry including 20 North 
American FMT practice sites.   
Limitations: Follow-up beyond 6 months is not yet available. 
Impact: The effectiveness and safety of FMT is similar in a real-world experience to that reported in 
research studies.  
Short summary: Approximately 90% of patients who undergo FMT for C. difficile infection can expect to 
be cured of the infection with few serious side effects due to FMT. 
